Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination

There is limited knowledge on durability of neutralization capacity and antibody affinity maturation generated following two versus three doses of SARS-CoV-2 mRNA vaccines in naïve versus convalescent individuals (hybrid immunity) against the highly transmissible Omicron BA.1, BA.2 and BA.3 subvariants. Virus neutralization titers against the vaccine-homologous strain (WA1) and Omicron sublineages are measured in a pseudovirus neutralization assay (PsVNA). In addition, antibody binding and antibody affinity against spike proteins from WA1, BA.1, and BA.2 is determined using surface plasmon resonance (SPR). The convalescent individuals who after SARS-CoV-2 infection got vaccinated develop hybrid immunity that shows broader neutralization activity and cross-reactive antibody affinity maturation against the Omicron BA.1 and BA.2 after either second or third vaccination compared with naïve individuals. Neutralization activity correlates with antibody affinity against Omicron subvariants BA.1 and BA.2 spikes. Importantly, at four months post-third vaccination the neutralization activity and antibody affinity against the Omicron subvariants is maintained and trended higher for the individuals with hybrid immunity compared with naïve adults. These findings about hybrid immunity resulting in superior immune kinetics, breadth, and durable high affinity antibodies support the need for booster vaccinations to provide effective protection from emerging SARS-CoV-2 variants like the rapidly spreading Omicron subvariants.

The emergence of Omicron (B.1.1.529/BA.1) variant of SARS-CoV-2 in November 2021, and its rapid spread across the globe, resulted in designation of Omicron as a variant of concern (VOC). Viral spike protein of the Omicron variant contains higher number (>30) of mutations compared to other variants, raising concerns that Omicron is resistant to neutralizing antibodies generated following SARS-CoV-2 vaccination or infection, and a third vaccine dose was recommended to boost immunity.

Since then, several subvariants of Omicron emerged (BA.2 and BA.3), each with its own set of mutations (Supplementary Table S1). Thus far, the BA.2 demonstrates higher transmissibility compared with BA.1 and has reached dominance in several countries in Europe and...
In this study, we evaluated the capacity and durability of neutralizing antibodies and antibody affinity induced following mRNA-based (Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273) vaccination in naïve versus convalescent individuals (infection before vaccination) both at one-month after the second and third vaccinations and at 4 months post-3rd vaccination against vaccine-homologous WA1 and Omicron BA1, BA2 and BA3 subvariants.

### Results

**Neutralizing antibodies following second and third vaccination in naïve and convalescent adults against SARS-CoV-2 WA1 and Omicron subvariants**

In this study, we evaluated immune response following mRNA-based (Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273) vaccination in a cohort of 81 adults: either naïve (N = 50) or SARS-CoV-2 convalescent (infection before vaccination; N = 31) individuals both at peak (1 month) immune response after the second and third, as well as at 4 months post-3rd vaccination, against vaccine-homologous WA1 and Omicron BA1, BA2 and BA3 subvariants. There were no significant differences for age, sex, race, ethnicity, body mass index (BMI) or vaccine type between the two cohorts (Table 1 and Supplementary Table S2). The 31 convalescent individuals had SARS-CoV-2 infection between March - November 2020 (prior to emergence of Omicron). During that time, the predominant circulating strain in the US were the D614G strain and the Alpha variant prior to availability of mRNA vaccines. All subjects received the second dose of mRNA vaccines between January and February 2021 and a third vaccine dose between September-October 2021 either from Moderna (mRNA-1273) or from Pfizer (BNT162b2). The first two vaccine doses were homologous for each participant. The boosters were either homologous or heterologous as shown in the Supplementary Table S2, but we don’t have enough power to compare differences in immune response to homologous vs. heterologous vaccines due to the low number of heterologous boosted participants in the study. None of the participants reported SARS-CoV-2 breakthrough infection following vaccination. Since most of the participants received the BNT162b2 vaccine we did not segregate the antibody responses between the vaccine types. Therefore, all data analyses were conducted irrespective of the specific vaccine administered. Blood samples were collected 1 month after the second dose as well as 1 month and 4 months after the third vaccine dose (Fig. 1a, b).

Virus neutralizing titers were measured using pseudovirus neutralization assay (PsVNA) against the SARS-CoV-2 vaccine homologous WA1, as well as Omicron BA1, BA2 and BA3 subvariants that were previously shown to correlate well with neutralization titers measured with authentic SARS-CoV-2 in plaque reduction neutralization tests (1, 11). A PsVNA50 titer of 1:60 was used as a seropositive cut-off based on current understanding of neutralizing antibody as correlate of protection against COVID-19 (9).

Ninety-four percent (94%) of previously naïve individuals had positive WA1-neutralizing antibody titers (≥1:60) at 1 month after the second vaccination with geometric mean titers (GMT) of 396. Following the third vaccine dose, 100% of naïve adults were seropositive with 5.9-fold average increase in neutralization titers (GMT = 2333) compared with the second vaccination. However, by four months after the third vaccine dose, the neutralization titers were 3.2-fold lower (GMT = 729) with 96% naïve individuals with PsVNA50 ≥ 1:60 (Fig. 1c).

In comparison with the naïve group, 97% of SARS-CoV-2 convalescent individuals were seropositive after two vaccinations with higher PsVNA50 titers (GMT = 1680) against vaccine-homologous WA1. After a third vaccination, WA1 neutralization titers increased by 2-fold (GMT = 3501) with 100% seropositivity. Importantly, the convalescent cohort maintained high titers after 4 months post-third vaccine dose with only 1.7-fold drop in neutralization titers (GMT = 2024) and 100% seropositivity (Fig. 1c). These findings confirmed earlier reports on the superiority of hybrid immunity, and further demonstrate the longevity of higher vaccine homologous WA1 neutralizing titers compared with vaccinated naïve individuals.

Neutralization titers were significantly reduced against all three Omicron subvariants compared with WA1 (Fig. 1d). After two vaccinations of naïve individuals only 12–16% had seropositive neutralization titers ≥1:60 against BA1, BA2, and BA3 with 22-25-fold reduction in PsVNA50 titers compared with WA1. However, after a third vaccine dose, 88–90% individuals demonstrated Omicron cross-neutralizing antibodies with PsVNA50 GMTs ranging between 243-312 (only 6–10-fold lower neutralization titers than WA1). In comparison, the convalescent cohort maintained higher responses against the Omicron subvariants BA1, BA2 and BA3, after two vaccinations (56–71% seropositive, GMTs=87–146), that were further boosted after the third vaccine dose reaching 97%-100% seropositivity and GMTs ranging between 338 and 534 (7–10-fold lower than WA1 at 1-month post-third vaccine dose) (Fig. 1d).

### Durability of neutralizing antibodies following 3rd vaccination in naïve vs convalescent individuals

We also determined the persistence of neutralizing antibodies against Omicron subvariants at four months post 3rd vaccine dose (Fig. 1e and Supplementary Figure S1) in a subset of vaccinated individuals. The reduction in neutralization titers for the naïve group (GMT of 90-99) was 2.5–3.2-fold, while reduction in titers for the convalescent group (GMT of 194-233) was 1.6-2.2-fold compared with 1-month post-3rd vaccination time-point, similar to the reduction in neutralization titers against WA1 (Fig. 1c). Both the GMT and the percentage of individuals with neutralization titers above 1:60 against Omicron subvariants were higher for the convalescent group (88%) compared with the naïve...
group (70–74%) at 4-months post-third vaccination (Supplementary Fig. S1 and Fig. 1e). It is important to note that after the 3rd vaccine dose, the neutralizing antibody responses against the vaccine homologous WA1 were not statistically different between the naïve vs. convalescent groups, while the difference between the responses to the highly transmissible Omicron subvariant BA.2 was statistically lower at 1 month (\( p = 0.0295 \)) but not at 4 months after the third vaccine dose (Fig. 1e). The neutralization titers against Omicron BA.3 were statistically higher for the convalescent group compared with the naïve group at 1 month post-second vaccination (\( p = 0.0005 \)), and at 1 month (\( p = 0.0005 \)) as well as 4 months (\( p = 0.0005 \)) after the third vaccine dose (Fig. 1e).

Fig. 1 | Neutralizing antibodies following second and third vaccination in naïve and convalescent adults against SARS-CoV-2 WA-1 and Omicron subvariants. a Overview of vaccination cohort, including 50 unexposed naïve (N; in blue) and 31 COVID-19 convalescent (C; in red) adults receiving second and third mRNA vaccination. b Timeline of SARS-CoV-2 vaccination and sample collection in the two adult cohorts. c-e SARS-CoV-2 neutralizing antibody titers in naïve (N; in blue) vaccination and convalescent adults (C; in red) one month after the second or third mRNA vaccination and four months post-3rd vaccination against SARS-CoV-2 WA1 and Omicron BA.1, BA.2 and BA.3. c-e PsVNA50 of post-2nd (Vx-2) or at 1 m and 4 m post-third dose (Vx-3) against WA1. Geometric mean PsVNA50 titers (GMT) are shown as black triangles and are presented for each vaccination time-point on top of the panel. Each data point represents an individual sample (circles). The horizontal dashed line indicates the seropositive cut-off for the neutralization titers (PsVNA50 of 60). Percent seropositivity (%) for each group was calculated as number of seropositive samples divided by total number of samples x 100 in the group. The limit of detection for the neutralization assay is 1:20. Any sample that does not neutralize SARS-CoV-2 at 20-fold dilution was given a value of 10 for representation and data analysis purposes. d Plots showing PsVNA50 titers at 1 m after second or third mRNA vaccination serum of naïve (N; in blue) and convalescent (C; in red) adults against WA1 and Omicron BA.1, BA.2 and BA.3. The fold-reduction in titers to Omicron BA.1 or BA.2 or BA.3 compared with WA1 are shown. e Comparisons of PsVNA50 titers against WA1 and Omicron BA.1, BA.2 and BA.3 for 1 m post-second or post-third mRNA vaccination or 4 m post-3rd vaccination from 50 naïve (N; in blue) vs. 31 convalescent (C; in red) adults. Percent seropositivity is color coded for each of the group. The fold-difference in titers between naïve vs convalescent cohorts are shown. Differences between naïve vs. convalescent cohorts were analyzed using Tukey’s pairwise multiple comparison test that controlled for age, sex and BMI as covariates and the two-sided statistically significant \( p \)-values are shown. Nonsignificant \( p \) values (\( p > 0.05 \)) are not shown. The data shown are average values of two experimental runs.
To identify potential role of sex on vaccination-induced immune response, we compared the neutralizing antibody response of males’ vs females after second and third SARS-CoV-2 mRNA vaccination in naïve vs. convalescent adults. The PsVNA50 titers against WA1 and the Omicron variants were not significantly different between males vs. females in either convalescent group or in the naïve group. However, at 4 months post-third vaccine dose, the convalescent males exhibited higher neutralization titers than convalescent females against WA1 (1.8-fold), BA.1 (2.4-fold), BA.2 (2.7-fold) and BA.3 (2.5-fold) (Supplementary Fig. S2).

The neutralizing antibody titers following second mRNA vaccination in convalescent individuals correlated significantly with the time interval between infection and first vaccination suggesting a longer time interval between infection and first-vaccination results in higher SARS-CoV-2 neutralization antibody response induced by vaccination (Supplementary Fig. S2). No correlation was observed for post-third vaccination neutralization titers and infection-vaccination time-interval, suggesting that with time, the antibody responses even in individuals with hybrid immunity reaches a plateau.

These findings demonstrated that hybrid immunity following infections with early SARS-CoV-2 strains followed by mRNA vaccination with the ancestral strain provides superior neutralizing antibody response with significantly higher cross-neutralization of Omicron subvariants BA.1, BA.2 and BA.3, either after two or three doses of mRNA vaccination.

Vaccination-induced binding antibodies against spike trimeric proteins of SARS-CoV-2 WA1 and Omicron BA.1 and BA.2 variants

Surface Plasmon Resonance (SPR) was used to measure total antibody binding against recombinant spike proteins derived from vaccine homologous WA1 and currently predominant circulating Omicron BA.1 and BA.2 subvariants as determined by Resonance Units (RU) (Fig. 2a and Supplementary Fig. S4). The purified recombinant SARS-CoV-2
spike proteins were captured to a Ni-NTA sensor chip with low protein density (200 RU) on the chip such as to measure monovalent interactions independent of the antibody isotype, as described before15–17. Antibody binding to the BA1 and BA2 spike proteins were lower than binding of the vaccine homologous WA1 spike after two or three mRNA vaccinations for both cohorts (Fig. 2a and Supplementary Fig. S4 and S5). The differences in spike-binding antibodies between the naïve vs. hybrid immunity groups were statistically significant after the second vaccine dose against Omicron BA1 (p < 0.0001) and BA2 (p = 0.0211) spikes, and against BA1 spike at 4 months after the third vaccine dose (p = 0.0068) (Fig. 2a).

**Antibody affinity of WA1 and Omicron spike-binding antibodies following SARS-CoV-2 mRNA vaccination in naïve vs convalescent individuals**

To determine qualitative difference in antibody avidity maturation against SARS-CoV-2 spike proteins induced following mRNA vaccination, antibody dissociation kinetics (off-rate constants), which describe the stability of the antigen-antibody complex, i.e., the fraction of complexes that decay per second in the dissociation phase, that are independent of antibody concentration were used as a surrogate for overall average avidity of polyclonal antibody were determined directly from the humoral polyclonal sample interaction with recombinant purified SARS-CoV-2 spike proteins of vaccine homologous WA1 as well as Omicron BA1 and BA2 using SPR in the dissociation phase only for the sensorgrams with Max RU in the range of 10–150 RU, as described before25–28. Previously, we showed that antibody kinetics measured under optimized SPR conditions primarily represent the monovalent interactions between the antibody-antigen complex, as antigen-antibody binding off-rates of the IgG and Fab interaction with protein antigens were similar29,30,31.

Antibody binding dissociation rates against WA1 spike were slower indicating higher binding affinity after the third vaccination compared with the second vaccination against the vaccine spike protein (Fig. 2b and Supplementary Fig. S6). The antibody binding affinity against WA1 in the hybrid immunity group trended higher than the naïve group at one month after the 2nd vaccine dose (1.6-fold), one month after the 3rd dose (2.5-fold) and four months after the 3rd dose (2.1-fold) but these differences did not reach statistical significance (Fig. 2b).

Antibody binding affinity against the spike protein of Omicron subvariants BA1 and BA2 trended lower compared with the WA1 spike, but an increase in antibody affinity (i.e., slower dissociation rates) was observed one month after the 3rd dose compared with post-2nd vaccine dose that was maintained at four months post-3rd vaccination (Supplementary Figure S6). Interestingly, binding antibody affinity were significantly higher for the hybrid immunity group compared with the naïve group against BA1 and BA2 spike proteins after the 2nd dose (p < 0.0001 and p = 0.0061, respectively), one month after the 3rd dose (p = 0.0031 and p = 0.0132, respectively) and at four months after the 3rd dose (p = 0.0024 for BA2 spike) (Fig. 2b and Supplementary Figs. S6 and S7).

The antibody evolution after mRNA vaccinations and their decay followed parallel trajectories with good correlation between PsVNA50 neutralizing antibody titers and spike antibody binding (Supplementary Fig. S8) as well as antibody affinity (Fig. 3). Importantly, individuals with hybrid immunity demonstrated durable higher neutralizing antibody titers and higher antibody affinity than naïve adults at least up to 4 months post-third vaccination against the Omicron subvariants, especially BA2 (Fig. 4), which recently has become dominant around the globe, and continues to evolve further.

**Discussion**

Recent infections with circulating SARS-CoV-2 Omicron subvariants (especially BA1 and BA2) are determined by multiple factors including immune escape due to specific amino acid mutations in the spike, the levels (specificity and affinity) of cross-reactive polyclonal antibodies elicited by prior infection and/or vaccination, and waning immunity15–17.

Our study demonstrates that a third vaccination significantly boosts neutralizing antibodies against the Omicron subvariants, including BA1 and BA2, as recently reported18, as well as BA3. But in our study, convalescent individuals with hybrid immunity showed better antibody response against the rapidly spreading Omicron BA1, BA2 and BA3 compared with vaccinated and boosted individuals with no history of prior infection. Our data and other studies suggest that Omicron BA3 may evade immunity acquired from vaccination slightly more efficiently than BA1 and BA219. Therefore, the need for an additional booster vaccination may vary based on the individual's infection/vaccination histories and the circulating strains, in addition to various risk factors. In addition, our study demonstrated a strong correlation between SARS-CoV-2 neutralization titers and spike-binding antibody affinity against Omicron subvariants BA1 and BA2 spikes. Importantly, even at four months after the third dose the antibody binding affinities against the Omicron subvariants BA1 and BA2 were maintained and trended higher for the individuals with hybrid immunity. Recently, Wratt et al., reported similar findings but our data expands the antibody analyses, including delineating antibody affinity maturation and persistence of protective immunity to the Omicron subvariants up to 4 months post-third SARS-CoV-2 mRNA vaccination30. Although hybrid immunity due to prior SARS-CoV-2 infection followed by vaccination leads to broader antibody responses, it is important to understand that any infection still comes with a risk of complications. The gradual drop in antibody titers following hybrid immunity, irrespective if the infection took place before or after vaccination, suggest the immunity wanes at similar rates following vaccination and breakthrough infections with eventual loss of protection against circulating SARS-CoV-2 strains21–24. A possible role of immune imprinting in SARS-CoV-2 immune response due to prior SARS-CoV-2 infection/vaccination or the original antigenic sin (OAS) hypothesis, whereby adults with B-cell memory due to prior exposure to seasonal coronaviruses25–27,33,34 requires further investigation. Recently, we observed anti-S2 cross-reactivity in naïve older children but not in the younger children (<4 years old), who share homology with HKU1, 229E and OC4333–35. OAS was also observed in mice immunization studies with seasonal CoV followed by SARS-CoV-2 spike26. Most of these cross-reactive antibodies do not neutralize SARS-CoV-2 and do not contribute to SARS-CoV-2 neutralization.

Our data along with previous studies suggest the presence of circulating memory B cells with expanded affinity-matured repertoires in convalescent individuals that are recalled by vaccination and likely to re-enter secondary germinal centers to undergo further somatic hypermutation (SHM) and antibody affinity maturation21–24. In naïve individuals, antibody affinity maturation post vaccination lags the convalescent group but may continue to evolve in the weeks following additional vaccine boosts. The breadth of variant recognition is likely to be impacted both by the antigenic distance between the infecting and vaccination strains, the rate of antibody affinity maturation through repeated GC seedings of memory B cells, and the time post-infection and last vaccination21–24.

The protective efficacy by vaccine-induced antibodies against emerging variants may be impacted by both specific amino acid mutations in the spike and the affinity of the polyclonal antibodies against the SARS-CoV-2 variants. An association was observed between high titers of low-affinity antibodies against RBD with the disease severity of COVID-19 patients17. In previous studies, we had demonstrated a strong correlation between antibody affinity and protection from highly pathogenic avian influenza viruses36–38 and a correlation with clinical benefit in patients infected with Zika virus39, Ebola virus40, influenza virus39 and COVID-1941. Therefore, in addition to virus
neutralization it is important to measure antibody affinity maturation against the SARS-CoV-2 spike not only for the vaccine strain, but also against spike proteins derived from the circulating variants of concern, that may influence the protective efficacy of vaccines against current and emerging SARS-CoV-2 variants of concern.

No breakthrough infections with Omicron were reported in our cohorts. However, it will be important to demonstrate the impact of high-affinity anti-BA.1/BA.2 antibodies not only on severe outcome (hospitalization/death) but also on the clinical course and viral loads in Omicron breakthrough infections. Based on the waning immunity, it is expected that naïve adults will potentially require another vaccine booster earlier (4–6 months post-third vaccination) than individuals with hybrid immunity to generate protective strong neutralizing antibodies especially against the rapidly spreading Omicron subvariants BA.2.12.1, BA.4 and BA.5. In summary, our study demonstrates that hybrid immunity provides superior immune kinetics, breadth, and durable high-affinity antibodies vs. vaccine-only immunity against Omicron sublineages up to four months post-third vaccination with mRNA vaccines.

**Methods**

**Study background, patient characteristics, vaccines**

Heat-inactivated de-identified samples were obtained from participants enrolled in the SPARTA (SARS2 Seroprevalence and Respiratory Tract Assessment) program in Athens, GA (USA) with written informed consent (Supplementary Table S1). The study procedures, informed consent, and sample collection for antibody affinity measurement were approved by the Institutional Review Board of the Emory University School of Medicine.

**Study design**

The study was a prospective, observational cohort study design. Participants were enrolled based on the availability of blood samples collected at least 1 month post-third vaccination with mRNA vaccines.

**Patients**

The study enrolled 71 adult participants, including 31 vaccine-exposed (65%) and 40 naïve adults (35%). Participants were stratified into vaccine-exposed and naïve groups based on their vaccination status.

**Vaccines**

All participants received the Pfizer-BioNTech or Moderna mRNA vaccines. The vaccine doses were administered according to the approved schedule.

**Sample processing and storage**

Blood samples were collected in EDTA tubes and stored at −80°C until analysis.

**Antibody affinity measurement**

Antibody affinity was measured using the PsVNA50 assay, which quantifies the concentration of antibodies that neutralize 50% of the virus at a designated concentration.

**Statistical analysis**

Correlation analysis was performed using nonlinear regression model and associated Spearman's correlation coefficients (r) and regression significance (p) are shown for two-sided statistical test.

**Figure 3**

Relationship of post-vaccination SARS-CoV-2 serum neutralizing antibodies in COVID convalescent and naïve adults with antibody affinity against SARS-CoV-2 spike protein. Correlation analysis between serum PsVNA50 neutralization antibody titers generated following second and third vaccination of COVID exposed (n = 31) and unexposed naïve (n = 50) adults against vaccine-matched SARS-CoV-2 WA1 (a) and Omicron BA.1 (b) and BA.2 (c), and antibody affinity to spike protein of corresponding SARS-CoV-2 strain. Correlation analysis was performed using nonlinear regression model and associated Spearman's correlation coefficients (r) and regression significance (p) are shown for two-sided statistical test.

**Supplementary Table S1**

| N | C |
|---|---|
| Naïve adults | Convalescent adults |
| 31 | 40 |
breakthrough infection following vaccination.

Supplementary Table S2. None of the participants reported SARS-CoV-2 infection-induced antibody response in naïve (blue) vs convalescent (red) adults shown as percent seropositivity of neutralization titers and spike antibody affinity against SARS-CoV-2 Omicron BA.2 following second and third mRNA vaccination.

Fig. 4 | Durability of vaccination-induced SARS-CoV-2 vaccination-induced immunity against Omicron BA.2. Schematic highlighting the durability of SARS-CoV-2 vaccination-induced antibody response in naïve (blue) vs convalescent (red) adults shown as percent seropositivity of neutralization titers and spike antibody affinity against SARS-CoV-2 Omicron BA.2 following second and third mRNA vaccination.

congent, and data collection documents were reviewed and approved by the WIRB-Copernicus Group Institutional Review Board (WCG IRB #202029060) and the University of Georgia. All patients provided written informed consent. Consent on this study included agreement for the use of remnant material for additional immunological assays at the time of study enrollment. Samples were tested in different antibody assays with approval from the U.S. Food and Drug Administration’s Research Involving Human Subjects Committee (FDA-RHSC) under exemption protocol ‘252-Determination- CBER-2020-08-19. All samples were tested in duplicates in a blinded fashion. Most absolute values and fold-change graphs were normalized to Log2 for statistical calculations.

Table 1 lists the summary of patient characteristics for this cohort. Supplementary Table S2 lists the extended demographics and vaccine/booster types, and the time point of sampling relative to the COVID-19 vaccination. Sex and/or gender was considered in the study design and was determined based on self-report by the study participants. All participants reported to be binary (either Male or Female).

Post-SARS-CoV-2 mRNA vaccination serum samples were collected after the second vibration and third vaccination from 31 convalescent individuals who were exposed to SARS-CoV-2 but not hospitalized (had confirmed SARS-CoV-2 infection between March and November 2020) prior to circulation of any of the Omicron lineages as well as naïve 50 healthy adults. During March – November 2020, the predominant circulating SARS-CoV-2 strains in the US were the D614G strain and the Alpha variant prior to vaccines being available in the US. All immune naïve individuals tested negative by RT-PCR for nucleic acid and did not report any COVID-like symptoms at any point during the study. They also tested antibody negative to SARS-CoV-2 spike, prior to vaccination. All subjects received mRNA vaccine either from Moderna (mRNA-1273) or from Pfizer (BNT162b2) at 4-week or 3-week intervals between doses, respectively, between January and February 2021. All of them then received a third mostly homologous vaccine booster dose in September-October 2021. The primary series with the first two vaccine doses were homologous for each vaccinee. The boosters were either homologous or heterologous as shown in the Supplementary Table S2. None of the participants reported SARS-CoV-2 breakthrough infection following vaccination.

Neutralization assay

Sera were evaluated in a qualified SARS-CoV-2 pseudovirus neutralization assay (PsVNA) using SARS-CoV-2 WA-1 strain and the three Omicron variant lineages: BA.1 (B.1.1.529), BA.2 and BA.3 (Supplementary Table S1). SARS-CoV-2 neutralizing activity measured by PsVNA correlates with PRNT (plaque reduction neutralization test with authentic SARS-CoV-2 virus) in previous studies. Pseudovirions were produced as previously described. Briefly, human codon-optimized cDNA encoding SARS-CoV-2 spike glycoprotein of the WAI/2020 and variants were synthesized by GenScript and cloned into eukaryotic cell expression vector pcDNA 3.1 between the BamHII and Xhol sites. Pseudovirions were produced by co-transfection Lenti-X 293 T cells with psPAX2 (gag/pol), pTrip-luc lentiviral vector and pcDNA 3.1 SARS-CoV-2-spike-deltaC19, using Lipofectamine 2000. The supernatants were harvested at 48 h post transfection and filtered through 0.45 µm membranes and titrated using 293T-ACE2-TMPRSS2 cells (HEK 293 T cells that express ACE2 and TMPRSS2 proteins).

Neutralization assays were performed as previously described. For the neutralization assay, 50 µL of SARS-CoV-2 S pseudovirions (counting ~200,000 relative light units) were pre-incubated with an equal volume of medium containing serial dilutions (20-, 60-, 180-, 540-, 1620-, 4860-, 14,580- and 43,740-fold dilution at the final concentration) of heat-inactivated serum at room temperature for 1 h. Then 50 µL of virus-antibody mixtures were added to 293T-ACE2-TMPRSS2 cells (104 cells/50 µL) in a 96-well plate. The input virus with all SARS-CoV-2 strains used in the current study were the same (2 × 104 relative light units/50 µL/well). After a 3 h incubation, fresh medium was added to the wells. Cells were lysed 24 h later, and luciferase activity was measured using One-Glo luciferase assay system (Promega, Cat# E6130). Antibody data was collected in MS Excel version 16.57. The assay of each serum was performed in duplicate, and the antibody neutralization titer was calculated using Prism 9 (GraphPad Software). Controls included cells only, virus without any antibody and positive sera. The limit of detection for the neutralization assay is 1:20. Any sample that does not neutralize SARS-CoV-2 at 20-fold dilution was given a value of 10 for representation and data analysis purposes. Two independent biological replicate experiments were performed for each sample and variation in PsVNA50 titers was <9% between replicates.

Antibody binding kinetics to SARS-CoV-2 spike proteins by Surface Plasmon Resonance

Steady-state equilibrium binding of post-SARS-CoV-2 vaccinated human polyclonal sample was monitored at 25 °C using a ProteOn surface plasmon resonance (BioRad). The purified recombinant SARS-CoV-2 spike proteins were captured to a Ni-NTA sensor chip with 200 resonance units (RU) in the test flow channels. Serial dilutions (10-50 and 250-fold) of freshly prepared samples in BSA-PBST buffer (PBS pH 7.4 buffer with Tween 20 and BSA) were injected at a flow rate of 50 µL/min (120 s contact duration) for the association, and dissociation was performed over a 600-s interval. Responses from the protein surface were corrected for the response from a mock surface and for responses from a buffer-only injection. Total antibody binding was calculated with BioRad ProteOn manager software (version 3.1). All SPR experiments were performed twice. In these optimized SPR conditions, the variation for each sample in duplicate SPR runs was <6%. The maximum resonance units (Max RU) shown in figures is for 10-fold diluted sample.

Antibody off-rate constants, which describe the stability of the antigen-antibody complex (i.e. the fraction of complexes that decays per second in the dissociation phase) were determined directly from the interaction of human polyclonal samples with recombinant purified SARS-CoV-2 proteins using SPR in the dissociation phase only for the sensorgrams with Max RU in the range of 10–150 RU and calculated using the BioRad ProteOn manager software for the heterogeneous sample model as described before. Off-rate constants were determined from two independent SPR runs.

Quantification and statistical analysis

Descriptive statistics were performed to determine the geometric mean titer values and were calculated using GraphPad. All experimental data to compare differences among groups were analyzed using lm4 and emmeans packages in R (RStudio version 1.1.463).
The demographic characteristics of these study participants are shown in Supplementary Table S2. Since age, sex, and the body mass index (BMI) can be biologically plausible confounders, data were analyzed for statistical significance between convalescent vs unexposed naive groups to control for age, sex, and BMI as covariates (predictor variables) using a multivariate linear regression model. To ensure robustness of the results, absolute measurements were log2-transformed before performing the analysis. For comparisons between the vaccine cohorts (factor variable), pairwise comparisons were extracted using ‘emmeans’ and Tukey-adjusted p values were used for denoting significance to reduce Type I error due to multiple testing. The tests were two-sided tests. The differences were considered statistically significant with a 95% confidence interval when the p value was less than 0.05.

Samples were allocated randomly to each test group and tested blindly (researcher was blinded to sample identity) to minimize selection bias or detection bias. There were no exclusion criteria. All samples and data were used for analysis and presented in the study.

**Reporting Summary**
Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**Data availability**
All data are shown in the manuscript figures and supplementary information. The complete dataset for this study are provided in the Source Data file. Source data are provided with this paper.

**References**
1. Kumar, S., Thambiraja, T. S., Karuppanan, K. & Subramaniam, G. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. *J. Med Virol.* **94**, 1641–1649 (2022).
2. Mahase, E. Covid-19: What do we know about omicron sublineages? *BMJ* **376**, e264 (2022).
3. Callaway, E. Why does the Omicron sub-variant spread faster than the original? *Nature* **602**, 556–557 (2022).
4. Tang, J. et al. Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern. *iScience* **24**, 103006 (2021).
5. Ravichandran, S. et al. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. *Sci. Transl. Med.* **12**, eabc3539 (2020).
6. Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from asymptomatic SARS-CoV-2 infection. *Nat. Med.* **27**, 1205–1211 (2021).
7. Khurana, S. et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. *Sci. Transl. Med.* **3**, 85ra48 (2011).
8. Tang, J. et al. Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients. *Nat. Commun.* **12**, 1221 (2021).
9. Ravichandran, S. et al. Systemic and mucosal immune profiling in asymptomatic and symptomatic SARS-CoV-2-infected individuals reveal unlinked immune signatures. *Sci. Adv.* **7**, eabf6533 (2021).
10. Khurana, S. et al. Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design. *Cell Host Microbe* **27**, 262–276 e264 (2020).
11. Khurana, S. et al. Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. *Nat. Med.* **22**, 1439–1447 (2016).
12. Ravichandran, S. et al. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. *Sci. Transl. Med.* **12**, eabc3539 (2020).
13. Ravichandran, S. et al. SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19. *Nat. Immunol.* **22**, 1452–1464 (2021).
14. Ravichandran, S. et al. Longitudinal antibody repertoire in “mild” versus “severe” COVID-19 patients reveals immune markers associated with disease severity and resolution. *Sci. Adv.* **7**, eabf2467 (2021).
15. Borz, R. et al. Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar’s experience. *J. Glob. Health* **12**, 05004 (2022).
16. Abu-Raddad, L. J. et al. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. *N. Engl. J. Med.* **386**, 1804–1816 (2022).
17. Altarawneh, H. N. et al. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. *N. Engl. J. Med.* **386**, 1288–1290 (2022).
18. Yu, J. et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. *N. Engl. J. Med.* **386**, 1579–1580 (2022).
19. Arora, P. et al. Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3. *Lancet Infect. Dis.* **22**, 766–767 (2022).
20. Wratli, P. R. et al. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. *Nat. Med.* **28**, 496–503 (2022).
21. Altarawneh, H. N. et al. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection includes Broad Reactivity to the S2 Subunit. *mbio* **11**, e01991–20 (2020).
22. Bates, T. A. et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. *Sci. Immunol.* **7**, eabn8014 (2022).
23. Goldberg, Y. et al. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. *N. Engl. J. Med.* **386**, 2201–2212 (2021).
24. Nguyen-Contant, P. et al. S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection includes Broad Reactivity to the S2 Subunit. *Nature* **596**, 1288–1290 (2022).
25. Shrock, E. et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. *Science* **370**, eabd4250 (2020).
26. Lapp, S. A. et al. Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection. *PLoS One* **16**, e0256482 (2021).
27. Pichler, D. et al. Marked Increase in Avidity of SARS-CoV-2 Antibodies 7-8 Months After Infection Is Not Diminished in Old Age. *J. Infect. Dis.* **224**, 764–770 (2021).
28. Sokal, A. et al. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. *Cell* **184**, 1201–1213 e1214 (2021).
29. Mazzoni, A. et al. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19. *J. Clin. Invest.* **131**, e149150 (2021).
30. Cho, A. et al. Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. *Nature* **600**, 517–522 (2021).
31. Pape, K. A. et al. High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines. *Cell Rep.* **37**, 109823 (2021).
32. Kim, W. et al. Germline centre-driven maturation of B cell responses to mRNA vaccination. *Nature* **604**, 141–145 (2022).
33. Servellita, V. et al. Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California. *Nat. Microbiol.* **7**, 277–288 (2022).
34. Roltgen, K. et al. mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition. *medRxiv* (2021).
35. Hendriks, J. et al. High Titters of Low Affinity Antibodies in COVID-19 Patients Are Associated With Disease Severity. Front Immunol. 13, 867716 (2022).
36. Khurana, S. et al. H5 N-terminal beta sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine. Vaccine 32, 6421–6432 (2014).
37. Verma, S. et al. Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies. J. Virol. 86, 12283–12293 (2012).
38. Ravichandran, S. et al. Differential human antibody repertoires following Zika infection and the implications for serodiagnostics and disease outcome. Nat. Commun. 10, 1943 (2019).
39. Davey, R. T. Jr. et al. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. Lancet Respir. Med 7, 951–963 (2019).
40. Lee, Y. et al. SARS-CoV-2 mRNA vaccine induced higher antibody affinity and IgG titers against variants of concern in post-partum vs non-post-partum women. EBioMedicine 77, 103940 (2022).
41. Neerukonda, S. N. et al. Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. PLoS One 16, e0248348 (2021).

Acknowledgements
We thank Keith Peden and Basil Golding for their insightful review of the manuscript. We thank Carol Weiss for providing plasmid clones expressing SARS-CoV-2 variants. The authors would like to thank all SPARTA program participants. The authors thank Hannah Hanley and Debbie Bratt for program coordination, as well as the member of the SPARTA collection, processing, and analysis teams, including Brittany Baker, Charlotte Bolle, Courtney Briggs, Jasmine Burris, Jasper Gattiker, Omar Hamwy, Lauren Howland, Hana J, Katie Mailloux, Cleopatra Smith, Terrie Waits, Emma Whitesell, and the entire staff at the University of Georgia Clinical and Translational Research Unit (CTRU). The antibody characterization work described in this manuscript was supported by FDA’s MCMi grant #OCET 2021-1585 to S.K and intramural FDA-CBER COVID-19 supplemental funds. The SPARTA program was supported by the National Institute of Allergy and Infectious Diseases (NIAID), U.S. National Institutes of Health (NIH), Department of Health and Human Services contract 75N93019C00052, and the University of Georgia (US) grant UGA-001. T.M.R is also supported by the Georgia Research Alliance (US) grant GRA-001. The CTRU was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number ULTR02378. The funders had no role in study design, data collection and analysis, interpretation, writing, decision to publish, or preparation of the manuscript. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Author contributions
All authors read and approved the final version of the manuscript. Designed research: S.K. and T.R. Performed research: L.B., G.G., F.Z. and S.K. Collected clinical samples and provided clinical data: D.F. and T.R. T.R. verified the underlying data. Contributed to Writing: H.G. and S.K. S.K. and H.G. verified the underlying data.

Competing interests
The authors declare no competing interests.

Ethics
The study at CBER, FDA, was conducted with de-identified samples and all assays performed fell within the permissible usages in the original consent. Antibody assays were performed with approval from the U.S. Food and Drug Administration’s Research Involving Human Subjects Committee (FDA-RIHSC) under exemption protocol ‘252-Determination-CBER-2020-08-19.

Additional information

Supplementary information
The online version contains supplementary material available at https://doi.org/10.1038/s41467-022-32298-w.

Correspondence
and requests for materials should be addressed to Surender Khurana.

Peer review information
Nature Communications thanks the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information
is available at http://www.nature.com/reprints

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022.

Nature Communications | (2022) 13:4617